Navigation Links
Is yakult helpful in the treatment of irritable bowel syndrome?
Date:9/9/2008

SIBO is a common feature in IBS and in fact may be directly related to the genesis of IBS symptoms. An ERBHAL on a lactulose breath test may indicate SIBO. Antibiotics and elemental diets have been shown to be effective in treating SIBO, but the efficacy of probiotics is untested. A pilot study was undertaken to determine the effect of L. strain Shirota (Yakult(R)) on intestinal fermentation patterns of IBS patients. After 6 week of treatment with 1 x 65 mL dose of Yakult(R) daily, 9 of 14 patients (64%) completing the study had reversal of ERBHAL, with the median time of first rise increasing from 45 to 75 min (P = 0.03). Furthermore, symptoms improved in those in whom ERBHAL was corrected. The results indicate that Yakult(R) alters fermentation patterns suggesting a reduction in SIBO. ERBHAL can also indicate rapid small intestinal transit and therefore, in order to confirm the effect of Yakult(R) on SIBO, future studies will include monitoring of transit time in addition to placebo control.

A research article to be published on August 28, 2008 in the World Journal of Gastroenterology addresses this question. The research team was led by Peter Gibson and his colleagues at Monash University, Box Hill Hospital. The pilot trial was undertaken to determine whether a probiotic could have an effect on SIBO. Currently, SIBO is managed by antibiotics and/or elemental diets, the side effects and practicalities of which make them undesirable options. Probiotics may provide a safe alternative. The results of the pilot trial warrant a well powered, double blind, placebo-controlled trial.

The effect of probiotics on SIBO had not previously been investigated, but after taking Yakult(R) daily for 6 wk, there was a significant shift in the time of first rise on the lactulose breath test indicating a reduction in SIBO. If these findings are confirmed by further research, Yakult(R) may be a safe and effective alternative for the management of this patient group.


'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related biology news :

1. Statin does not appear helpful for children with learning disabilities caused by genetic disorder
2. Study confirms that low-calorie sweeteners are helpful in weight control
3. Fish oil -- helpful or harmful?
4. Breastfeeding boost IQ in infants with helpful genetic variant
5. New once-a-week treatment for type 2 diabetes developed by Mount Sinai researcher
6. Landmark study opens door to new cancer, aging treatments
7. Common treatment to delay labor decreases preterm infants risk for cerebral palsy
8. UC Davis researchers define characteristics, treatment options for XXYY syndrome
9. Why a common treatment for prostate cancer ultimately fails
10. Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
11. Childrens national co-leads nationwide study of landmark sickle cell treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
Breaking Biology Technology: